The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
Proteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms of this resistance remain unclear. The aim of our study is to assess the expression...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/5/951 |
| _version_ | 1797395343417016320 |
|---|---|
| author | Pawel Robak Dariusz Jarych Damian Mikulski Izabela Dróżdż Edyta Węgłowska Aleksandra Kotkowska Małgorzata Misiewicz Piotr Smolewski Konrad Stawiski Wojciech Fendler Janusz Szemraj Tadeusz Robak |
| author_facet | Pawel Robak Dariusz Jarych Damian Mikulski Izabela Dróżdż Edyta Węgłowska Aleksandra Kotkowska Małgorzata Misiewicz Piotr Smolewski Konrad Stawiski Wojciech Fendler Janusz Szemraj Tadeusz Robak |
| author_sort | Pawel Robak |
| collection | DOAJ |
| description | Proteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms of this resistance remain unclear. The aim of our study is to assess the expression of previously described genes that may influence the resistance to bortezomib treatment at the mRNA level (<i>ABCB1</i>, <i>CXCR4</i>, <i>MAF</i>, <i>MARCKS</i>, <i>POMP</i>, <i>PSMB5</i>, <i>RPL5</i>, <i>TXN,</i> and <i>XBP1</i>) and prognosis of MM patients. mRNA expression was determined in 73 MM patients treated with bortezomib-based regimens (30 bortzomib-sensitive and 43 bortezomib-refractory patients) and 11 healthy controls. <i>RPL5</i> was significantly down-regulated in multiple myeloma patients as compared with healthy controls. Moreover, POMP was significantly up-regulated in MM patients refractory to bortezomib-based treatment. In multivariate analysis, high expression of <i>PSMB5</i> and <i>CXCR</i> and autologous stem cell transplantation were independent predictors of progression-free survival, and high expression of <i>POMP</i> and <i>RPL5</i> was associated with shorter overall survival. |
| first_indexed | 2024-03-09T00:33:07Z |
| format | Article |
| id | doaj.art-08763897c2944183bfce005e02ef0e1e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T00:33:07Z |
| publishDate | 2021-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-08763897c2944183bfce005e02ef0e1e2023-12-11T18:20:17ZengMDPI AGCancers2072-66942021-02-0113595110.3390/cancers13050951The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with BortezomibPawel Robak0Dariusz Jarych1Damian Mikulski2Izabela Dróżdż3Edyta Węgłowska4Aleksandra Kotkowska5Małgorzata Misiewicz6Piotr Smolewski7Konrad Stawiski8Wojciech Fendler9Janusz Szemraj10Tadeusz Robak11Department of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, PolandLaboratory of Personalized Medicine, Bionanopark, 93-465 Lodz, PolandDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, PolandDepartment of Clinical Genetics, Medical University of Lodz, 92-213 Lodz, PolandLaboratory of Personalized Medicine, Bionanopark, 93-465 Lodz, PolandDepartment of Hematology, Medical University of Lodz, 93-510 Lodz, PolandDepartment of Hematology, Medical University of Lodz, 93-510 Lodz, PolandDepartment of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, PolandDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, PolandDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, PolandDepartment of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, PolandDepartment of Hematology, Medical University of Lodz, 93-510 Lodz, PolandProteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms of this resistance remain unclear. The aim of our study is to assess the expression of previously described genes that may influence the resistance to bortezomib treatment at the mRNA level (<i>ABCB1</i>, <i>CXCR4</i>, <i>MAF</i>, <i>MARCKS</i>, <i>POMP</i>, <i>PSMB5</i>, <i>RPL5</i>, <i>TXN,</i> and <i>XBP1</i>) and prognosis of MM patients. mRNA expression was determined in 73 MM patients treated with bortezomib-based regimens (30 bortzomib-sensitive and 43 bortezomib-refractory patients) and 11 healthy controls. <i>RPL5</i> was significantly down-regulated in multiple myeloma patients as compared with healthy controls. Moreover, POMP was significantly up-regulated in MM patients refractory to bortezomib-based treatment. In multivariate analysis, high expression of <i>PSMB5</i> and <i>CXCR</i> and autologous stem cell transplantation were independent predictors of progression-free survival, and high expression of <i>POMP</i> and <i>RPL5</i> was associated with shorter overall survival.https://www.mdpi.com/2072-6694/13/5/951bortezomibCXCR4gene expressionmultiple myelomaPOMPPSMB5 |
| spellingShingle | Pawel Robak Dariusz Jarych Damian Mikulski Izabela Dróżdż Edyta Węgłowska Aleksandra Kotkowska Małgorzata Misiewicz Piotr Smolewski Konrad Stawiski Wojciech Fendler Janusz Szemraj Tadeusz Robak The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib Cancers bortezomib CXCR4 gene expression multiple myeloma POMP PSMB5 |
| title | The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib |
| title_full | The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib |
| title_fullStr | The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib |
| title_full_unstemmed | The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib |
| title_short | The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib |
| title_sort | prognostic value of whole blood psmb5 cxcr4 pomp and rpl5 mrna expression in patients with multiple myeloma treated with bortezomib |
| topic | bortezomib CXCR4 gene expression multiple myeloma POMP PSMB5 |
| url | https://www.mdpi.com/2072-6694/13/5/951 |
| work_keys_str_mv | AT pawelrobak theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT dariuszjarych theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT damianmikulski theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT izabeladrozdz theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT edytawegłowska theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT aleksandrakotkowska theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT małgorzatamisiewicz theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT piotrsmolewski theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT konradstawiski theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT wojciechfendler theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT januszszemraj theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT tadeuszrobak theprognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT pawelrobak prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT dariuszjarych prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT damianmikulski prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT izabeladrozdz prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT edytawegłowska prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT aleksandrakotkowska prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT małgorzatamisiewicz prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT piotrsmolewski prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT konradstawiski prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT wojciechfendler prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT januszszemraj prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib AT tadeuszrobak prognosticvalueofwholebloodpsmb5cxcr4pompandrpl5mrnaexpressioninpatientswithmultiplemyelomatreatedwithbortezomib |